Natalizumab: 12 agencies, 2006–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 19.2 years separate the first record, 26 Oct 2006 at AWMSG (Wales), from the most recent, 28 Jan 2026 at NICE (England).
CONITEC (Brazil) changed its position: not recommended on 26 Aug 2013, recommended by 13 Nov 2020, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for natalizumab, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 11 of 33 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for natalizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 33 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess natalizumab, on 26 Oct 2006; CIPM (Spain) did not open a file until 13 Dec 2023 — an unusually long tail of 17.2 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 14 years in total.
9 of the 12 agencies here assessed natalizumab more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
natalizumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for natalizumab reads 19 recommended, 5 not recommended, 2 deferred to NICE and 1 advice, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 23 Dec 2025 | Single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS) for the foll… | excluded, NICE appraised | source |
| HAS (France) | 9 Jul 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2025 | Relapsing-remitting multiple sclerosis (RRMS) | Recommended | source |
| NYE METODER (Norway) | 20 Oct 2024 | Behandling av relapserende remitterende multippel sklerose (RRMS). | not introduced | source |
| PHARMAC (New Zealand) | 22 Dec 2023 | Relapsing-remitting multiple sclerosis (RRMS) | PTAC advice: Medium | source |
28 further decisions for natalizumab, across 12 agencies, are not shown here. They include the most recent record on file, 28 Jan 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 19 further source documents.
Related molecules
- teriflunomide — divergent outcome (recommended vs restricted) on a shared indication
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
Coverage: 33 decisions for natalizumab from 12 agencies, 2006 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.